Movement Alert｜Abivax S.A. Rises 5.1% in Regular Trading, Trading at $95.33

Market Focus

Sep 28

On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.

Within the Biotechnology sector where Abivax S.A. belongs, individual stock performance was sharply divergent. Among individual stocks, Kodiak Sciences Inc. up 155.58%, Moderna, Inc. down 2.65%, Amgen down 0.05%, Gilead Sciences down 0.19%, Regeneron Pharmaceuticals down 3.45%.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is being evaluated in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with the company planning to submit a New Drug Application before year-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/news/1125023974"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125023974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125023974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-28 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125023974","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 5.1% in Regular Trading, Trading at $95.33","media":"Market Focus","content":"<p><p>On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.</p><p>Within the Biotechnology sector where Abivax S.A. belongs, individual stock performance was sharply divergent. Among individual stocks, Kodiak Sciences Inc. up 155.58%, Moderna, Inc. down 2.65%, Amgen down 0.05%, Gilead Sciences down 0.19%, Regeneron Pharmaceuticals down 3.45%.</p><p>Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is being evaluated in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with the company planning to submit a New Drug Application before year-end.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 5.1% in Regular Trading, Trading at $95.33</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 5.1% in Regular Trading, Trading at $95.33\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-28 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.</p><p>Within the Biotechnology sector where Abivax S.A. belongs, individual stock performance was sharply divergent. Among individual stocks, Kodiak Sciences Inc. up 155.58%, Moderna, Inc. down 2.65%, Amgen down 0.05%, Gilead Sciences down 0.19%, Regeneron Pharmaceuticals down 3.45%.</p><p>Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is being evaluated in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with the company planning to submit a New Drug Application before year-end.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1125023974","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125023974","pubTimestamp":1790605598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.Within the Biotechnology sector where Abivax S.A. belongs, individual stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"走势警报|Abivax S.A. 常规交易中上涨 5.1%，交易价格为 95.33 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On September 28, Abivax S.A. rose 5.1% in regular trading, trading at $95.33 USD/share, with Turnover of $44.18 million.Within the Biotechnology sector where Abivax S.A. belongs, individual stock performance was sharply divergent. Among individual stocks, Kodiak Sciences Inc. up 155.58%, Moderna, Inc. down 2.65%, Amgen down 0.05%, Gilead Sciences down 0.19%, Regeneron Pharmaceuticals down 3.45%.Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is being evaluated in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, with the company planning to submit a New Drug Application before year-end.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}